Chiesi puts down $200M+ to col­lab­o­rate with Af­fi­body for res­pi­ra­to­ry dis­eases

3 years ago
Deals
R&D

Rare dis­ease tri­als can't find enough pa­tients. It's forc­ing the FDA to re­think its ap­proach

3 years ago
FDA+
In Focus

Cal­i­for­nia 'won't be do­ing busi­ness' with Wal­greens af­ter abor­tion pill de­ci­sion, Gov. New­som says

3 years ago
Pharma

Biden pro­pos­es ex­tend­ing Medicare price ne­go­ti­a­tions to more drugs

3 years ago
FDA+
Law

Am­per­sand snags $50M as Flag­ship fo­cus­es ther­a­peu­tics on de­sired tar­gets on­ly 

3 years ago
Financing
Startups

Janssen's neu­ro di­vi­sion churns out Rap­port, a new $100M biotech from Third Rock’s clin­i­cal da­ta hunt

3 years ago
Financing
Startups

On­col­o­gy spe­cial­ist Volas­tra brings in PhI drug from Am­gen, nabs $60M in Se­ries A

3 years ago
Financing
Deals

FDA de­lays re­view of Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter da­ta up­date

3 years ago
Cell/Gene Tx
FDA+

Noe­ma Phar­ma rais­es $112M Se­ries B to ad­vance CNS dis­or­der pipeline with Roche can­di­dates

3 years ago
Financing
R&D

Mer­ck un­wraps full PhI­II da­ta on the cen­ter­piece from its $11.5B Ac­celeron buy­out: #ACC23

3 years ago
R&D

Large bio­phar­ma com­pa­nies cull about 40 im­muno-on­col­o­gy pro­grams over the last two quar­ters

3 years ago
R&D

FDA ax­es di­ag­nos­tic re­quire­ment for Lil­ly's Verzenio + en­docrine ther­a­py in cer­tain breast can­cer pa­tients

3 years ago
Pharma
FDA+

As­traZeneca, Dai­ichi Sankyo tease new En­her­tu da­ta — but de­tails re­main un­der wraps

3 years ago
R&D
Pharma

Phar­ma in­dus­try lob­bies Con­gress for so­lu­tion to pri­mate short­age af­ter in­dict­ments for al­leged smug­gling

3 years ago
Pharma

Lex­i­con dives ‘in­to the dark’ days fol­low­ing heart fail­ure hos­pi­tal­iza­tions with new cam­paign

3 years ago
Pharma
Marketing

Mer­ck’s oral cho­les­terol-low­er­ing drug shows sim­i­lar ef­fi­ca­cy to in­jectable pre­de­ces­sors as it moves to PhI­II: ...

3 years ago
R&D

Ac­cel­er­at­ed ap­proval in­com­ing? Mod­er­na 'hope­ful' for per­son­al­ized can­cer vac­cine

3 years ago
Pharma
FDA+

Thou­sands of com­plaints and lab records in 'bags of scrap': FDA in­spects Cipla site in In­dia

3 years ago
FDA+
Manufacturing

Or­chard lines up mon­ey for pro­posed Lib­meldy ex­pan­sion; Har­bour touts PhI­II

3 years ago
News Briefing

Men­tal health-fo­cused atai chops 30% of staff to 'fur­ther fo­cus' on loom­ing read­outs

3 years ago
People

With PhII suc­cess, Bridge­Bio wades deep­er in­to dwarfism drug de­bate

3 years ago
R&D

Aclaris shares halved af­ter mid-stage skin dis­or­der fail

3 years ago
R&D

French CAR-T biotech Mnemo Ther­a­peu­tics shut­ters US op­er­a­tions

3 years ago
People
Cell/Gene Tx

Red Tree, RA Cap­i­tal lead $108M in­fu­sion in­to Bicara and its bi­func­tion­al I/O drug

3 years ago
Financing
First page Previous page 366367368369370371372 Next page Last page
A service from the Financial Times